A Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602 in Type 2 Diabetic Patients

Diabetes Mellitus, Type 2 Clinical Trial

Official title:

A Phase 2a, Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSCD-0602 in Type 2 Diabetic Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01280695
• Other study ID #: MSDC-0602-C002
• Status: Completed
• Phase: Phase 2
• First received: January 20, 2011
• Last updated: March 17, 2014
• Start date: February 2011
• Est. completion date: June 2011

Study information

• Verified date: March 2014
• Source: Metabolic Solutions Development Company
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to assess the safety and tolerability of MSDC-0602 and to evaluate the reduction in fasting plasma glucose in patients with Type 2 diabetes.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 129
• Est. completion date: June 2011
• Est. primary completion date: June 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 75 Years

Eligibility

Patients must meet all of the following inclusion criteria to be eligible for enrollment into the study:

Inclusion Criteria:

1. Males and females with Type 2 diabetes (fasting plasma glucose =126 mg/dL at screening, glycosylated hemoglobin [HbA1c] >7 and =10%, and Insulin C-peptide >1 ng/mL). Patients can be naïve to diabetes therapy or if taking metformin should be on a stable dose level for a period of at least 3 months prior to screening visit (no dose limit).

2. Between the ages of 18-75 years, inclusive.

3. Females should be either postmenopausal (at least 12 months since last menses) or surgically sterilized (bilateral tubal ligation or hysterectomy). Menopausal status will be verified by a follicle-stimulating hormone (FSH) test. If FSH levels are below 40 mIU/mL, some method of birth control must be used. Those with bilateral tubal ligation must also use a barrier method of birth control. In addition, all females must have a negative pregnancy test at Screen and Day 15 regardless of childbearing potential. For postmenopausal women only, if FSH levels are above 40 mIU/mL and serum pregnancy results are indeterminant, the subject will be assessed as not pregnant.

Males with female partners of child-bearing potential must agree to use adequate contraceptive methods (including a condom, plus one other form of contraception) if engaging in sexual intercourse.

4. Body Mass Index (BMI) = 25 kg/m2 and = 45 kg/m2 (inclusive).

5. Willing and able to make a screening visit to the clinic and six visits over a 10 week period.

6. Willing and able to sign an informed consent document indicating understanding the purpose of and procedures required for the study and willingness to participate in the study.

Subject Exclusion Criteria:

1. Use of TZDs or diabetes medications other than metformin (generic or Glucophage®) 3 months prior to screening.

2. History of diabetic ketoacidosis or hyperosmolar non-ketotic coma.

3. Fasting plasma glucose in excess of 240 mg/dl at screening

4. History of heart failure (including CHF) or previous cardiovascular event (myocardial infarct, by-pass surgery, or PTCA) within the past 6 months prior to screening.

5. ALT and/or AST levels that equal or exceed twice the upper limit of normal; bilirubin levels that exceed 2 mg/dL; serum creatinine >1.5 mg/dL in men or > 1.4 mg/dL in women.

6. History of nephropathy, neuropathy, or retinopathy within 6 months of screening.

7. Use of glucocorticoids (oral, injectible, intraarticular, or chronic inhaled) or weight-loss drugs within 3 months of randomization.

8. Current or recurrent disease that may affect the action, absorption or disposition of the study treatment, or clinical or laboratory assessments.

9. Current or history of severe or unstable disorder (medical or psychiatric) requiring treatment that may make the patient unlikely to complete the study.

10. Febrile illness within the 5 days prior to Visit 1.

11. Known history of HIV, hepatitis B, or hepatitis C.

12. Clinically significant findings on physical examination, including BP, pulse rate and 12-lead ECG.

13. Blood pressure greater than 160/100 mmHg. Patients with elevated BP (<160/100 mmHg) with or without current treatment will be allowed at the discretion of the Principal Investigator (PI) and primary care physician. Individuals with hypertension must have been stabilized to the current treatment regimen for at least 6 weeks prior to screening.

14. Change in BP or lipid-lowering medication within 6 weeks or change in dose of metformin or thyroid replacement within 3 months prior to screening.

15. Known or suspected intolerance or hypersensitivity to the study drugs, closely related compounds or any of their stated ingredients.

16. History of alcohol or drug abuse within 6 months of Screening.

17. Have participated in an investigational study or received an investigational drug within 30 days or 5 half-lives (whichever is longer) prior to study drug administration.

18. Blood donation of 1 pint or more within 56 days of screening.

19. Plasmapheresis or plasma donation within 30 days of screening.

20. Single 12-lead ECG demonstrating a QTcB >450 msec at Screening. A single repeat ECG may be done at the Investigator's discretion.

21. Any surgical or medical condition which may significantly alter the absorption of any drug substance including, but not limited to, any of the following: history of major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, bowel resection, gastric bypass, gastric stapling, or gastric banding, currently active inflammatory bowel syndrome.

22. Evidence of clinically relevant pathology that could interfere with the study results or put the patient's safety at risk.

23. Malignancy, including leukemia and lymphoma (not including basal cell skin cancer) within the last 5 years.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 2

Intervention

Drug:
• Placebo
Placebo Capsules
• MSDC-0602 100 mg
MSDC-0602 100 mg Capsules
• MSDC-0602 250 mg
MSDC-0602 250 mg Capsules
• MSDC-0602 250 mg
MSDC-0602 500 mg Capsules
• Pioglitazone
Pioglitazone 45 mg Capsules

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Metabolic Solutions Development Company

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change From Baseline in Fasting Plasma Glucose	To characterize the reduction in fasting plasma glucose in response to three different doses of MSDC-0602 Tablets as compared to placebo following once-daily dosing for 28 consecutive days in patients with Type 2 diabetes.	Baseline and 28 days	No
Secondary	Change From Baseline in HbA1c	To explore the drug effect difference in the reduction in hemoglobin A1c in response to three different doses of MSDC-0602 and pioglitazone (45 mg Actos®) as compared to placebo following once-daily dosing for 28 consecutive days in patients with Type 2 diabetes.	Baseline and 28 days	No
Secondary	Change From Baseline in Body Weight	To characterize the effects of three different doses of MSDC-0602 and pioglitazone as compared to placebo on hematocrit, body weight, and edema following once-daily dosing for 28 consecutive days in patients with Type 2 diabetes.	Baseline and 28 days	No
Secondary	Change From Baseline in Hematocrit	To characterize the effects of three different doses of MSDC-0602 and pioglitazone as compared to placebo in hematocrit following once-daily dosing for 28 consecutive days in patients with Type 2 diabetes.	Baseline and 28 days	No
Secondary	Change in Fasting Plasma Insulin	To characterize the effects of 3 different doses of MSDC-0602 and pioglitazone as compared to placebo on insulin following once-daily dosing for 28 consecutive days	Baseline and 28 days	No
Secondary	Change From Baseline in High Molecular Weight Adiponectin	To evaluate the effects of three different doses of MSDC-0602 and pioglitazone as compared to placebo on biomarkers of inflammatory status (high molecular weight adiponectin) following once-daily dosing for 28 consecutive days in patients with Type 2 diabetes.	Baseline and 28 days	No